LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 3, Pages e001792
Publisher
BMJ
Online
2021-03-03
DOI
10.1136/jitc-2020-001792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
- (2019) Matthew D. Tucker et al. Cancer Medicine
- Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
- (2019) Hao Chen et al. Frontiers in Immunology
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
- (2019) A Marabelle et al. ANNALS OF ONCOLOGY
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy
- (2018) Emily Wynja et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report
- (2018) Won Jin Ho et al. Journal for ImmunoTherapy of Cancer
- Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
- (2018) Evidio Domingo-Musibay et al. Journal for ImmunoTherapy of Cancer
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member
- (2016) Arno G. Beer et al. Oncotarget
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- An integrative approach to predicting the functional effects of non-coding and coding sequence variation
- (2015) Hashem A. Shihab et al. BIOINFORMATICS
- Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
- (2014) J S Ross et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Down expression ofLRP1Bpromotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer
- (2013) Shaobin Ni et al. CANCER SCIENCE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Abstract 4060: Use of small animal MRI and cone-beam CT for image-guided radiotherapy of orthotopic tumors in mice
- (2012) Jinzi Zheng et al. CANCER RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
- (2011) Sergey I Nikolaev et al. NATURE GENETICS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells
- (2010) H Prazeres et al. ONCOGENE
- Ectodomains of the LDL Receptor-Related Proteins LRP1b and LRP4 Have Anchorage Independent Functions In Vivo
- (2010) Martin F. Dietrich et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started